Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

/PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) has entered into an exclusive license agreement with Intas Pharmaceuticals Limited ("Intas") for the...

Related Keywords

Cintas ,Antalya ,Turkey ,Australia ,Canada ,Shanghai ,China ,United Kingdom ,Mexico ,United States ,South Africa ,Poland ,Xuhui ,India ,Songjiang ,Jilin ,Greece ,Georgia ,Chinese ,American ,British ,Asia Pacific ,Fosun Pharma ,Paul Tredwell ,Jason Zhu ,Binish Chudgar ,Prnewswire Shanghai Henlius Biotech Inc ,European Commission ,Intas Pharmaceuticals Limited ,Accord Healthcare Ltd ,Journal Of The American Medical Association ,Drug Administration ,European Medicines Agency ,Intas Pharmaceuticals Ltd ,Business Development ,Southeast Asia ,Henlius Biotech ,Middle East ,North Africa ,Executive Director ,Chief Executive Officer ,Chief Financial Officer ,Senior Vice President ,Chief Business Development Officer ,Managing Director ,Executive Vice President ,American Medical Association ,Nature Medicine ,British Journal ,Small Cell Lung Cancer ,Non Small Cell Lung Cancer ,Esophageal Cancer ,Colorectal Cancer ,Practice Guidelines ,Immune Checkpoint Inhibitor ,China Guidelines ,Plasma Therapy ,Gene Therapy ,Good Manufacturing Practice ,Xuhui Plant ,Songjiang First Plant ,Henlius ,